Octave Strengthens Clinical Expertise in MS and Neurodegenerative Disease – Read the Release

Contact Us

Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies

September 27, 2024inByCommentNo Comments
Click here

© 2025 Octave Bioscience, Inc | 1440 O’Brien Drive, Suite B, Menlo Park, CA 94025 

Connect with us